Natural History of Multiple Sclerosis: Have Available Therapies Impacted Long-Term Prognosis?

Neurologic Clinics

Volumn 29, Issue 2, 2011, Pages 309-321

  Trojano, Maria ^a   Paolicelli, Damiano ^a   Tortorella, Carla ^a   Iaffaldano, Piero ^a   Lucchese, Guglielmo ^a   Di Renzo, Vita ^a   D'Onghia, Mariangela ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Disease modifying drugs; Long term prognosis; Multiple sclerosis; Observational study; Propensity score; Randomized trial

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE;

DISABILITY; DISEASE COURSE; DRUG EFFICACY; MULTIPLE SCLEROSIS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

DISABLED PERSONS; DISEASE PROGRESSION; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS; PRODUCT SURVEILLANCE, POSTMARKETING; PROGNOSIS; TREATMENT OUTCOME;

EID: 79952839371     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ncl.2010.12.008     Document Type: Review

References (53)

1. Weinshenker B.G., Bass B., Rice G.P., et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989, 112(Pt 1):133-146.
2. Confavreux C., Vukusic S., Moreau T., et al. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000, 343(20):1430-1438.
3. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo controlled trial. Neurology 1993, 43:655-661.
4. The IFNb Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995, 45:1277-1285.
5. Jacobs L.D., Cookfair D.L., Rudick R.A., et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996, 39:285-294.
6. PRISMS (Prevention of Relapses and Disability by Interferon b-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferonb-1a in relapsing/remitting multiple sclerosis. Lancet 1998, 352:1498-1504.
7. PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001, 56:1628-1636.
8. Johnson K.P., Brooks B.R., Cohen J.A., et al. Copolymer 1 reduces relapse rate and improves disability in relapsing remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995, 45:1268-1276.
9. Jacobs L.D., Beck R.W., Simon J.H., et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000, 343:898-904.
10. Comi G., Filippi M., Barkhof F., et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study. Lancet 2001, 357:1576-1582.
11. Kappos L., Polman C.H., Freedman M.S., et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndrome. Neurology 2006, 67:1242-1249.
12. Kappos L., Freedman M.S., Polman C.H., et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007, 370:389-397.
13. Kappos L., Freedman M.S., Polman C.H., et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009, 8:987-997.
14. Rudick R.A., Cutter G.R., Baier M., et al. Estimating long term effects of disease-modifying drug therapy in multiple sclerosis patients. Mult Scler 2005, 11:626-634.
15. Bermel R.A., Weinstock-Guttman B., Bourdette D., et al. Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study. Mult Scler 2010, 16(5):588-596.
16. Kappos L., Traboulsee A., Constantinescu C., et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 2006, 67:944-953.
17. Ebers G.C., Rice G., Konieczny A., et al. The interferon beta-1b 16-year long-term follow-up study: the final results. Neurology 2006, 66(Suppl 2):A32.
18. Ebers G.C., Traboulsee A., Li D., et al. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry 2010, 81(8):907-912.
19. Johnson K.P., Brooks B.R., Ford C.C., et al. Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial. Mult Scler 2003, 9:585-591.
20. Johnson K.P., Ford C.C., Lisak R.P., et al. Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data. Acta Neurol Scand 2005, 111:42-47.
21. Ford C.C., Johnson K.P., Lisak R.P., et al. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler 2006, 12(3):309-320.
22. Ford C., Goodman A.D., Johnson K., et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler 2010, 16(3):342-350.
23. Trojano M., Russo P., Fuiani A., et al. The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNb exposure in multiple sclerosis. Mult Scler 2006, 12:1-8.
24. Trojano M., Pellegrini F., Fuiani A., et al. New natural history of interferon beta-treated relapsing multiple sclerosis. Ann Neurol 2007, 61:300-306.
25. Brown M.G., Kirby S., Skedgel C., et al. How effective are disease modifying drugs in delaying progression in relapsing-onset MS?. Neurology 2007, 69:1498-1507.
26. Trojano M., Pellegrini F., Paolicelli D., et al. Real-life impact of early interferonβ-therapy in relapsing multiple sclerosis. Ann Neurol 2009, 66:513-520.
27. Debouverie M., Moreau T., Lebrun C., et al. A longitudinal observational study of a cohort of patients with relapsing remitting multiple sclerosis treated with glatiramer acetate. Eur J Neurol 2007, 14:1266-1274.
28. Carra A., Onaha P., Halfon J., et al. The impact of glatiramer acetate on progression of disability over a decade of continuous therapy. Mult Scler 2007, 13(Suppl 2):S68.
29. Miller A., Spada V., Beerkircher D., et al. Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing remitting multiple sclerosis. Mult Scler 2008, 14:494-499.
30. Noseworthy J.H. How much can we learn from long-term extension trials in multiple sclerosis?. Neurology 2006, 67:930-931.
31. McKee M., Britton A., Black N., et al. Methods in health services research. Interpreting the evidence: choosing between randomised and nonrandomised studies. BMJ 1999, 319:312-315.
32. Dobre D., van Veldhuisen D.J., DeJongste M.J.L., et al. The contribution of observational studies to the knowledge of drug effectiveness in heart failure. Br J Clin Pharmacol 2007, 64:406-414.
33. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ 1996, 312:1215-1218.
34. MacMahon S., Collins R. Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies. Lancet 2001, 357:455-462.
35. Feinstein A.R. Clinical biostatistics 1977, Mosby, London, p.16-20.
36. Matthews D.E., Farewell V.T. Using and understanding medical statistics 1988, revised, Karger, Basel (Switzerland). 2nd edition.
37. Rochon P.A., Gurwitz J.H., Sykora K., et al. Reader's guide to critical appraisal of cohort studies:1. Role and design. BMJ 2005, 330:895-897.
38. Wolfe R.A. Observational studies are just as effective as randomized clinical trials. Blood Purif 2000, 18:323-326.
39. Normand S.L.T., Sykora K., Li P., et al. Readers guide to critical appraisal of cohort studies: 3. Analytical strategies to reduce confounding. BMJ 2005, 330:1021-1023.
40. Rosenbaum P.R., Rubin D.B. The central role of the propensity score in observational studies for causal effects. Biometrika 1983, 70:41-55.
41. Rosenbaum P.R., Rubin D.B. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984, 79:516-524.
42. Hirano K., Imbens G.W. Estimation of causal effects using propensity score weighting: an application to data on right heart catheterization. Health Serv Outcomes Res Methodol 2001, 2:259-278.
43. Lunceford J.K., Davidian M. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Stat Med 2004, 23:2937-2960.
44. Vukusic S., Confavreux C. Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis. J Neurol Sci 2003, 206:135-137.
45. D'Agostino R.B. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998, 17:2265-2281.
46. Boggild M., Palace J., Barton P., et al. Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator. BMJ 2009, 339:b4677.
47. Ebers G. Natural history of multiple sclerosis. McAlpine's multiple sclerosis 1998, Churchill Livingstone, London, p. 191-221. 3rd edition. A. Compston, G. Ebers, H. Lassmann (Eds.).
48. D'Agostino R.B., D' Agostino R.B. Estimating treatment effects using observational data. JAMA 2007, 297(3):314-316.
49. Lin D.Y., Psaty B.M., Krommal R.A. Assessing the sensitivity of regression results to unmeasured confounders in observational studies. Biometrics 1998, 54:948-963.
50. Rubin D.B. The design versus the analysis of observational studies for causal effects: parallels with the design of randomized studies. Stat Med 2007, 26:20-36.
51. Ebers G.C., Reder A.T., Traboulsee A., et al. Long-term follow-up of the original interferon-β1b trial in multiple sclerosis: design and lessons from a 16-year observational study. Clin Ther 2009, 31:1724-1736.
52. Trojano M., Pellegrini F., Paolicelli D., et al. Observational studies: propensity score analysis of non-randomized data. Int MS J 2009, 16(3):90-97.
53. Hennekens C.H., Buring J.E., Manson J.E., et al. Lack of effect of longterm supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996, 334:1145-1149.